 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
4 News |  |
| 123456» |
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Journal: Dalpiciclib plus aromatase inhibitor versus neoadjuvant chemotherapy for ER-positive, HER2-negative breast cancer. (Pubmed Central) - May 15, 2025
This study indicates that the combination of dalpiciclib and AI elicits comparable responses and demonstrates improved safety profiles when compared to NCT in patients with HR+ HER2 negative breast tumors. Furthermore, RCB and pCR may not serve as optimal endpoints for evaluating the efficacy of CDK4/6i-based NET.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P2 trial, Circulating tumor DNA: DNADalHR: ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer (clinicaltrials.gov) - May 14, 2025
P2, N=393, Not yet recruiting, Sponsor: Peking University People's Hospital
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Pegylated rhG-CSF (mecapegfilgrastim) / Jiangsu Hengrui Pharma
Enrollment closed, Trial completion date, Trial primary completion date: Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer (clinicaltrials.gov) - May 14, 2025
P2, N=132, Active, not recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Furthermore, RCB and pCR may not serve as optimal endpoints for evaluating the efficacy of CDK4/6i-based NET. Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Jan 2025
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Efficacy and safety of dalpiciclib plus toremifene in advanced HR-positive HER2-negative breast cancer as first-line treatment: A multicenter, single-arm phase II trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4180;
P2
The combination of dalpiciclib and toremifene indicated a manageable, expected safety profile. This regimen may offer an viable first-line treatment option for HR+/HER2- mBC, especially for patients intolerant to aromatase inhibitors.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Epidaza (chidamide) / Chipscreen
Dalpiciclib plus chidamide in HR+/HER2- advanced breast cancer following CDK4/6 inhibitor treatment failure: Final results of a phase Ib trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4167;
P1
Our results revealed that dalpicilib plus chidamide achieved promising efficacy and safety in HR+/HER2- BC. The combination of dalpiciclib and chidamide may serve as an alternative treatment strategy in HR+/HER2- BC patients following CDK4/6i therapy failure.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Efficacy and safety of dalpiciclib plus fulvestrant and pyrotinib in HR+, HER2-low advanced breast cancer following CDK4/6 inhibitor and aromatase inhibitor: A Bayesian optimal phase ? trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4057;
P2
Among these patients, 21 (70.0%) received abemaciclib, and 10 (33.3%) received palbociclib and ribociclib. Our results indicated that dalpiciclib plus fulvestrant and pyrotinib achieves promising efficacy and safety in in HR+, HER2-low advanced BC patients following CDK4/6i and AI treatment.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Epidaza (chidamide) / Chipscreen
Dalpiciclib combined with chidamide and letrozole as neoadjuvant therapy for HR-positive, HER2-negative early or locally advanced breast cancer: A single-arm, prospective, exploratory clinical study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4022;
P4
Our results showed that the combination of dalpiciclib, chidamide and letrozole demonstrates an acceptable safety profile and promising clinical efficacy, suggesting its potential as an alternative fully oral, chemotherapy-free neoadjuvant treatment for HR-positive, HER2-negative early or locally advanced breast cancer. Further research is needed to validate these findings.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Phase Ib/II study of fluzoparib in combination with dalpiciclib in patients with locally advanced or metastatic sarcoma. (Hall A - Posters and Exhibits; Poster Bd #: 16) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2059;
P2
Part 2 to evaluate safety and efficacy is currently recruiting pts. TRAEs with an incidence of ?30% and any grade ?3 TRAEs.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Erbitux (cetuximab) / Eli Lilly
Cetuximab plus dalpiciclib in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma. (Hall A - Posters and Exhibits; Poster Bd #: 434) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1455;
P2
TRAEs with an incidence of ?30% and any grade ?3 TRAEs. Dalpiciclib combined with cetuximab was well-tolerated and demonstrated potentially favorable efficacy in patients with anti-PD-1-resistant, HPV-negative R/M HNSCC.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Biomarkers of neoadjuvant dalpiciclib in patients with operable HER2-negative luminal B breast cancer in the DANCER trial. (Hall A - Posters and Exhibits; Poster Bd #: 193) - Apr 23, 2025 - Abstract #ASCO2025ASCO_779;
P2
Dalpiciclib combined with cetuximab was well-tolerated and demonstrated potentially favorable efficacy in patients with anti-PD-1-resistant, HPV-negative R/M HNSCC. Patients with operable HER2-negative luminal B breast cancer who exhibit early ctDNA clearance, MammaPrint low-risk status, GSTM1 deletion, increased pRb/CDK4 expression, and higher plasma CCL4/CCL19 levels may derive substantial benefit from neoadjuvant dalpiciclib therapy.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2 (Hall B1) - Apr 23, 2025 - Abstract #ASCO2025ASCO_676;
P3
These data support the use of Dalp for treating HR+/HER2- early BC. Efficacy outcomes.*Kaplan
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Erbitux (cetuximab) / Eli Lilly
New P2 trial: Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC (clinicaltrials.gov) - Apr 21, 2025
P2, N=98, Recruiting, Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New trial: Efficacy and safety of dalsiris in combination with an adjuvant aromatase inhibitor in patients with HR+/HER2- locally advanced breast cancer: a multicenter, cohort study (EUDRACT) - Apr 2, 2025
P=N/A, N=300, Not yet recruiting, Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P4 trial: To evaluate the efficacy of trastuzumab + pyrotinib + dalpiciclib (EUDRACT) - Apr 2, 2025
P4, N=161, Not yet recruiting, Sponsor: Xiangya Hospital, Central South University; Xiangya Hospital, Central South University
- || Review, Journal: CDK4/6 as a Therapeutic Target in HR+/HER2- Breast Cancer Cells-Current Treatment Status. (Pubmed Central) - Mar 28, 2025
Moreover, dalpiciclib is being investigated in HR+/HER2- BC treatment. This article will summarize clinical efficacy, recommendations, and differences in toxicity profile between palbociclib, ribociclib, and abemaciclib and will also discuss the possibility of using dalpiciclib in the treatment of breast cancer.
- INV-6452 / Ionova Life Sci
Discovery of INV-6452, a CDK2/4 inhibitor for the treatment of HR-positive HER2-negative breast cancer resistant to current CDK4/6 therapy (Section 53; Poster Board No: 20) - Mar 25, 2025 - Abstract #AACR2025AACR_5009;
This article will summarize clinical efficacy, recommendations, and differences in toxicity profile between palbociclib, ribociclib, and abemaciclib and will also discuss the possibility of using dalpiciclib in the treatment of breast cancer. Abstract is embargoed at this time.
- || Retrospective data, Review, Journal: A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer. (Pubmed Central) - Mar 19, 2025
Meanwhile, we recommend close monitoring and management of these potential side effects when utilizing these inhibitors in breast cancer treatment. https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023490499.
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, HRS-1358 / Jiangsu Hengrui Pharma
Trial primary completion date, Monotherapy: A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer (clinicaltrials.gov) - Mar 17, 2025
P1, N=102, Recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023490499. Trial primary completion date: Dec 2024 --> Jun 2025
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open: Adebrelimab Combined with Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer (clinicaltrials.gov) - Mar 13, 2025
P2, N=30, Recruiting, Sponsor: Harbin Medical University
Trial primary completion date: Dec 2024 --> Jun 2025 Not yet recruiting --> Recruiting
- ||| Retrospective data, Review, Journal, Adverse events: Hepatic Adverse Events with CDK4/6 Inhibitors: A systematic review combining meta-analysis and FAERS Database. (Pubmed Central) - Feb 17, 2025
Palbociclib, ribociclib, and abemaciclib caused liver damage, while dalpiciclib did not. The most common manifestations were elevated ALT and AST levels.
- || Retrospective data, Review, Journal: Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis. (Pubmed Central) - Feb 13, 2025
The combination of CDK4/6i and ET significantly improves PFS and OS compared to ET alone in both Asian and non-Asian patients with HR+/HER2-aBC. Although the magnitude of benefit appears to be independent of ethnicity, future clinical trials should devise a standardized method for stratifying patients by ethnicity to more effectively assess potential differences in treatment benefits.
- | Trial primary completion date: FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov) - Dec 27, 2024
P2, N=716, Recruiting, Sponsor: Fudan University
Although the magnitude of benefit appears to be independent of ethnicity, future clinical trials should devise a standardized method for stratifying patients by ethnicity to more effectively assess potential differences in treatment benefits. Trial primary completion date: Sep 2024 --> Dec 2024
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
Enrollment closed, Trial completion date, Real-world evidence: Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer (clinicaltrials.gov) - Dec 20, 2024
P=N/A, N=200, Active, not recruiting, Sponsor: Fudan University
Trial primary completion date: Sep 2024 --> Dec 2024 Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Feb 2025
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
Clinical, Journal, Real-world evidence, Real-world, Metastases: Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2-metastatic breast cancer patients: a multicenter study (YOUNGBC-28). (Pubmed Central) - Dec 19, 2024
P
Palbociclib, abemaciclib, and dalpiciclib demonstrated comparable efficacy in Chinese patients with advanced HR+/HER2- MBC. ClinicalTrials.gov identifier: NCT06344780.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Trial completion date, Trial termination: Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Dec 17, 2024
P1/2, N=46, Terminated, Sponsor: Henan Cancer Hospital
ClinicalTrials.gov identifier: NCT06344780. Trial completion date: Jan 2026 --> Jul 2024 | Active, not recruiting --> Terminated; Investigators' decision
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New trial: Albumin-bound Paclitaxel?Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC (clinicaltrials.gov) - Dec 1, 2024
P=N/A, N=52, Not yet recruiting, Sponsor: Fujian Medical University
- | Journal: Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer. (Pubmed Central) - Nov 18, 2024
Dalpiciclib plus fulvestrant is effective and comparatively safe in postmenopausal women with hormone receptor-positive and HER2-negative breast cancers. Dalpiciclib, buparlisib, fulvestrant, and ribociclib cause neutropenia, severe depression, adverse gastroenterological effects, and adverse hepatological effects, respectively.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P2 trial: Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 12, 2024
P2, N=35, Recruiting, Sponsor: Peking University
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P4 trial: Prospective, randomized, cohort clinical study of Dalpicilib combined with letrozole or neoadjuvant chemotherapy in the treatment of ER high expression luminal A early breast cancer (EUDRACT) - Nov 10, 2024
P4, N=40, Recruiting, Sponsor: The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P4 trial: A single arm, multicenter, exploratory clinical study of CDK4/6 inhibitor dalpiciclib combined with letrozole, pyrotinib maleate and trastuzumab in the preoperative treatment of stage II-III triple positive breast cancer (TPBC) (EUDRACT) - Nov 10, 2024
P4, N=40, Not yet recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
A phase I, prospective exploratory clinical study of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for patients with HR-positive, HER2-positive early or locally advanced breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2170;
- The clinical benefits of CDK 4/6 inhibitors and biomarker interactions on HR+/HER2- advanced breast cancer patients: an updated pairwise meta-analysis of randomized controlled trials and network meta-analysis (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1738;
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
A Phase II study of dalpiciclib combined with letrozole, pertuzumab and trastuzumab as neoadjuvant therapy in HR+/HER2+ breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1386;
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Dalpiciclib versus placebo in combination with letrozole or anastrozole as first-line treatment for women with HR+/HER2- advanced breast cancer: prespecified final analysis of progression-free survival of the phase 3 DAWNA-2 trial. (Hemisfair Ballroom 1-2) - Nov 1, 2024 - Abstract #SABCS2024SABCS_987;
- A multicenter, single-arm, phase II clinical trial of oral CDK4/6 inhibitor darciclib in combination with endocrine therapy in adjuvant treatment for hormone receptor-positive, HER2-negative female breast cancer. (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_977;
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Dalpiciclib plus endocrine therapy for visceral crisis in advanced breast cancer: a multicenter, prospective, external controlled phase 2 study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_893;
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P2 trial: OBU-BC-II-164: Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer (clinicaltrials.gov) - Oct 20, 2024
P2, N=100, Not yet recruiting, Sponsor: Peking University
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P3 trial: Dalpicilib-Enhanced Vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer (clinicaltrials.gov) - Oct 15, 2024
P3, N=1388, Active, not recruiting, Sponsor: Fudan University
- ||| Journal, Adverse events: Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system. (Pubmed Central) - Oct 8, 2024
Notably, our analysis found novel safety signals linked to CDK4/6 inhibitors, including nail-related disorders such as onychoclasis, nail disorder, and nail discoloration, and psychiatric concerns, including eating disorders and emotional disorder. Overall, the present study identified several new safety signals of CDK4/6 inhibitors, as well as differences among various drugs within the CDK4/6 category, through the use of the FDA FAERS, which deserve more careful monitoring in the clinic.
- | Enrollment change: BCTOP-L-M05: SNF Platform Study of HR+/ HER2-advanced Breast Cancer (clinicaltrials.gov) - Oct 4, 2024
P2, N=620, Recruiting, Sponsor: Fudan University
Overall, the present study identified several new safety signals of CDK4/6 inhibitors, as well as differences among various drugs within the CDK4/6 category, through the use of the FDA FAERS, which deserve more careful monitoring in the clinic. N=140 --> 620
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P3 trial: PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer (clinicaltrials.gov) - Sep 25, 2024
P3, N=307, Active, not recruiting, Sponsor: Zhimin Shao
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P4 trial: An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer (clinicaltrials.gov) - Sep 24, 2024
P4, N=30, Not yet recruiting, Sponsor: Jiangsu Famous Medical Technology Co., Ltd.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial: An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer (clinicaltrials.gov) - Sep 20, 2024
P=N/A, N=30, Not yet recruiting, Sponsor: Liu Shu
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Adebrelimab Combined with Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer (clinicaltrials.gov) - Sep 19, 2024
P2, N=30, Not yet recruiting, Sponsor: Harbin Medical University
- | Retrospective data, Journal, Metastases: First?line endocrine therapy for hormone receptor positive and HER?2 negative metastatic breast cancer: A Bayesian network meta?analysis. (Pubmed Central) - Sep 9, 2024
Considering the effect on OS and PFS together with adverse reactions, safety, medical compliance and route of administration, PalboAI was found to be the optimal treatment for HR+/HER2-mBC. However, additional head-to-head clinical trials are warranted to confirm these findings.
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
P1 data, Journal, Combination therapy, Metastases: Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study. (Pubmed Central) - Sep 4, 2024
P1/2
The recommended phase III dose of dalpiciclib was 150?mg. ClinicalTrials.gov identifier: NCT03481998.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Epidaza (chidamide) / Chipscreen
New P2 trial, Metastases: Exploration of Dalpiciclib + Tucidinostat in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor (clinicaltrials.gov) - Aug 15, 2024
P2, N=155, Not yet recruiting, Sponsor: Beijing 302 Hospital
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P2 trial: Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer (clinicaltrials.gov) - Aug 13, 2024
P2, N=30, Not yet recruiting, Sponsor: Fudan University
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, HRS-1358 / Jiangsu Hengrui Pharma
Enrollment status, Trial primary completion date, Monotherapy: A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer (clinicaltrials.gov) - Aug 7, 2024
P1, N=102, Recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
ClinicalTrials.gov identifier: NCT03481998. Enrolling by invitation --> Recruiting | Trial primary completion date: Jun 2024 --> Dec 2024
- | Phase classification: FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov) - Aug 6, 2024
P2, N=716, Recruiting, Sponsor: Fudan University
Enrolling by invitation --> Recruiting | Trial primary completion date: Jun 2024 --> Dec 2024 Phase classification: P1/2 --> P2